UCSD Spinout Traversa Therapeutics Closes $2M VC Round for RNAi-Delivery Technology | GenomeWeb
Traversa Therapeutics, a spinout of the University of California, San Diego, said this week that it has closed a $2 million Series A round of venture capital financing to further develop its RNA interference-delivery technology.
A company official said Traversa will use the cash to ramp up manufacturing of the technology as a drug-screening tool — an application with modest market potential that Traversa hopes will pave the way to the more lucrative RNAi-based therapeutics space.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.